Emergent Biosolutions

EBS

Market cap $418M

Overview Fund Activity

7.79 USD

-0.04

0.51%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

7.79

0.00

0%

1 day

-0.51%

5 days

-2.99%

1 month

-14.11%

3 months

25.24%

6 months

34.54%

Year to date

-24.15%

1 year

13.23%

5 years

-92.33%

10 years

-76.03%

About: Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Employees: 900

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

131% more call options, than puts

Call options by funds: $2.69M | Put options by funds: $1.17M

38% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 39

37% more capital invested

Capital invested by funds: $176M [Q1] → $241M (+$65.1M) [Q2]

6.48% more ownership

Funds ownership: 66.6% [Q1] → 73.08% (+6.48%) [Q2]

5% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 40

0% more funds holding

Funds holding: 160 [Q1] → 160 (+0) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$15

93% upside

Avg. target

$15

93% upside

High target

$15

93% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co.

Raghuram Selvaraju

$15

Buy

Reiterated

3 Sep 2025

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about EBS published over the past 30 days

Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain

GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $17 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply TEMBEXA® (brincidofovir) oral suspension. This follows the U.S. Food and Drug Administration's (FDA) recent approval of the manufacturing scale-up of TEMBEXA® oral suspension. Oral suspension formulation is an important option for patients who may have trouble swallowing due to age or medical status.

Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain

Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness

GAITHERSBURG, Md., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that a contract modification has been executed in the amount of $56 million to supply ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) to the U.S. government.

Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

GAITHERSBURG, Md., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted). Deliveries are expected to begin this calendar year and are scheduled to be completed by March 2026.

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day

GAITHERSBURG, Md., Aug. 29, 2025 (GLOBE NEWSWIRE) -- In honor of International Overdose Awareness Day (IOAD) on August 31, Emergent BioSolutions (NYSE: EBS) is re-launching its Ready to Rescue public education campaign, which raises awareness of opioid emergencies and the importance of being prepared with NARCAN® Nasal Spray among young adults at college/university activations with Greek Life, wellness services and athletic departments. Together, Pro Football Hall of Famer and campaign spokesperson, Emmitt Smith, and Release Recovery founder and CEO, Zac Clark will lead inspiring conversations to break down the stigma around accidental opioid poisonings and empower students to be ready to save a life with over-the-counter NARCAN® Nasal Spray.

Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day

Emergent BioSolutions to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's senior management team will participate in the following investor conferences: Wells Fargo 20 th Annual Healthcare Conference September 4, 20253:00 pm ETWebcast link here One-on-one meetings HCW 27 th Annual Global Investment Conference September 9, 20251:30 PM ETWebcast link here One-on-one meetings Please contact your conference representative to request one-on-one meetings.

Emergent BioSolutions to Participate in Upcoming Investor Conferences

Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™

GAITHERSBURG, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) -- As opioid emergencies continue to be the leading cause of accidental death in the United States,1 Emergent BioSolutions (NYSE: EBS) is teaming up with Voices for Awareness and Facing Fentanyl Now in honor of National Fentanyl Prevention and Awareness Day™ on August 21, 2025. As part of this year's efforts, these leading advocacy organizations and its sponsors will bring their message to Times Square, NYC on the day with several high-visibility billboards that expose fentanyl risks and urge a nationwide call to action to reduce the stigma around opioid poisonings ensuring that more people can be prepared to save a life. Synthetic opioids, such as fentanyl, are a key driver of the opioid epidemic, contributing to nearly 70 percent of all overdose deaths.2 Its undetectable nature—lacking taste, smell, or visible characteristics—makes fentanyl particularly dangerous, and this partnership underscores a shared commitment to saving lives through increased public awareness.

Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™

Big Rallies Brewing? 3 Analyst Favorites to Watch Closely

Companies can receive a big boost on impressive results or promising news, and then it is a matter of maintaining momentum to ensure those gains aren't given back shortly after.

Big Rallies Brewing? 3 Analyst Favorites to Watch Closely

Emergent BioSolutions: Q2 Results Could Spark A Strong 2025 Rally

Emergent BioSolutions delivered a strong Q2 2025, beating its own guidance and showing major improvements in margins. EBS has a sound turnaround strategy that is showing signs of success. The company has some competitive advantages to maintain and grow market share.

Emergent BioSolutions: Q2 Results Could Spark A Strong 2025 Rally

Emergent BioSolutions Inc. (EBS) Q2 2025 Earnings Call Transcript

Emergent BioSolutions Inc. (NYSE:EBS ) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants Joseph C. Papa - CEO, President & Director Richard S.

Emergent BioSolutions Inc. (EBS) Q2 2025 Earnings Call Transcript

Emergent BioSolutions Reports Second Quarter 2025 Financial Results

GAITHERSBURG, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2025.

Emergent BioSolutions Reports Second Quarter 2025 Financial Results

See News Rankings

Charts implemented using Lightweight Charts™